Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 78Carcinoma, Non-Small-Cell Lung 43Nasopharyngeal Carcinoma 24Lung Neoplasms 23Breast Neoplasms 14Cholangiocarcinoma 13Lymphoma, Large B-Cell, Diffuse 12Neoplasm Metastasis 11Ovarian Neoplasms 10Lymphoma, Extranodal NK-T-Cell 10Recurrence 9Biliary Tract Neoplasms 9Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasms 6Nasopharyngeal Neoplasms 6Lymphoma 6Lymphoma, T-Cell, Peripheral 5Uterine Cervical Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 4Rectal Neoplasms 4Hodgkin Disease 4Head and Neck Neoplasms 4Gallbladder Neoplasms 4Colonic Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma of Lung 4Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell 3

Interventions

lenvatinib 3tislelizumab 2sintilimab 2theasinensin A 1sitravatinib 1S 1 (combination) 1Gemcitabine 1Cryosurgery 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Biliary Tract Cancer × Gemcitabine × Clear all
NCT05410197 2022-10-12

Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

Sun Yat-sen University

Phase 2 Unknown
43 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡